bendamustine / Generic mfg. - LARVOL DELTA

Single Center Experience: Bendamustine Associated Neutropenia with or without Pegfilgrastim (HOPA 2026) - "In progress"

Clinical • Chemotherapy-Induced Neutropenia • Febrile Neutropenia • Hepatology • Liver Failure • Neutropenia

Successful Treatment of Persistent and Relapsing COVID-19 with Ensitrelvir in a Patient with Obinutuzumab-Induced Long-Term B-Cell Depletion: A Case Report. (PubMed, Reports (MDPI)) - "Compared with remdesivir and molnupiravir, ensitrelvir achieves higher rates of SARS-CoV-2 antigen clearance and a more favorable viral shedding profile. Case Presentation: A 67-year-old Japanese man with follicular lymphoma had received obinutuzumab plus bendamustine, followed by obinutuzumab maintenance therapy...Three months prior to the current admission, the patient developed coronavirus disease 2019 (COVID-19) and was treated with a 10-day course of remdesivir and dexamethasone... Ensitrelvir may be an effective therapeutic option for the treatment of persistent or refractory COVID-19 in immunocompromised patients. Clinicians should recognize that patients treated with obinutuzumab may remain immunosuppressed for several years after therapy."

Journal • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • CRP

A Clinicopathological Study on Incidence of Enhancer of Zeste Homolog 2(EZH2) Mutations in Follicular Lymphoma and its Correlation with Histology (USCAP 2026) - "Forty-three patients received Bendamustine-Rituximab(B+R),18 patients received R-CHOP,5 patients received radiotherapy, and 22 patients were kept on observation. Our study shows the increased incidence of EZH2 mutations in follicular lymphomas as seen in the literature. The prognostic significance of an isolated EZH2 mutation in follicular lymphomas is thought to be aggressive, but we had contrary findings. However, routine screening for EZH2 mutations may help in triaging patients for targeted therapy with EZH2 inhibitors."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • EZH2

THE EXPERIENCE OF AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA ON DIALYSIS (EBMT 2026) - "In induction patients received bortezomib (100%), lenalidomide-containing courses - 17 patients (59%), anti-CD38-monoclonal antibodies - 8 pts (27%)...High doses of cyclophosphamide or etoposide with G-CSF were used to mobilize PBSC... Dialysis-dependent renal failure in MM patients is not a contraindication to autologous SCT. AutoSCT promotes a deeper hematological response, and achieving a renal response and independence from hemodialysis in patients. Adding bendamustine to conditioning does not have an advantage over melphalan monotherapy in patients with dialysis-dependent renal failure."

Clinical • IO biomarker • Atrial Fibrillation • Bone Marrow Transplantation • Cardiomyopathy • Cardiovascular • CNS Disorders • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Mucositis • Multiple Myeloma • Nephrology • Pneumonia • Respiratory Diseases • Septic Shock • CD34

AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A 10-YEAR SINGLE-CENTER EXPERIENCE (EBMT 2026) - "ASCT remains a critical therapeutic modality for multiple myeloma, yielding high short- and long-term survival rates in a contemporary cohort. Long-term follow-up data highlight the importance of risk stratification and can inform optimized transplant strategies. The addition of bendamustine to melphalan conditioning may improve outcomes in high-risk or extramedullary MM, though differences were not statistically significant."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Transplantation

PD-1 INHIBITOR PROLGOLIMAB ACHIEVES HIGH RESPONSE RATE BUT AUTO-HCT REMAINS ESSENTIAL FOR SUSTAINED PROLONGED REMISSION IN SECOND-LINE TREATMENT OF RELAPSED/REFRACTORY HODGKIN LYMPHOMA (PROLGO-HL) (EBMT 2026) - P2 | "If CR is not achieved pts are switched to combination therapy (Prolgo 1 mg/kg D1,15; Bendamustine 90 mg/m2 D1,2, 28-day cycle, for up to 3 cycles). This real-world study demonstrates high response rate within the Prolgo-HL protocol in patients with r/r cHL. However, significant relapse rate in early CR maintenance arm bring into question the benefit of omitting auto-HCT in unselected group of patients with r/r cHL. Further stratification of low risk patients needed to identify population for whom forgoing auto-HCT is feasible."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

FIVE-YEAR FOLLOW-UP OF NIVOLUMAB-BASED COMBINATIONS AND TRANSPLANT STRATEGY AFTER PD-1 INHIBITOR FAILURE IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (EBMT 2026) - "All patients were treated with combination of nivo (3 mg/kg or 40 mg every 2 weeks) and chemo- or targeted therapy: bendamustine 90 mg/m² D1,2 of a 28-day cycle (n=55), vinblastine 10 mg every 2 weeks (n=42), brentuximab vedotin (BV) 1.8 mg/kg every 3 weeks (n=20), or gemcitabine 800-1000 mg every 2 weeks (n=6). The use of combination regimens with CPI represents an effective and safe strategy. This approach is beneficial for patients who have failed multiple therapy lines including CPI, including its use as a bridge to allo-HCT, as well as for patients who are not candidates for transplantation."

Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Transplantation

ROLE OF TARGETED IMMUNE THERAPIES IN RELAPSED/REFRACTORY LYMPHOMA (HODGKINS): A MULTICENTER EXPERIENCE FROM VARIOUS TRANSPLANT CENTERS IN PAKISTAN. A LOWER MIDDLE INCOME COUNTRY PERSPECTIVE (EBMT 2026) - "All patients had received first-line ABVD followed by salvage ICE/GDP before immunotherapy (brentuximab vedotin ± bendamustine or alternative agents). Immunotherapy/ targeted therapy showed clinically relevant activity in heavily-pretreated RR-HL patients, allowing many patients to proceed to ASCT with a high remission rate. Toxicities were frequent, but overall manageable and with one death. Our results reiterate the feasibility of immunotherapy in RR-HL as a bridge to transplant in keeping with international experience, although more extensive prospective studies are required in South Asian cohorts."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Mucositis • Transplantation • TNFRSF8

AUTOLOGOUS TRANSPLANT IN T-CELL LYMPHOMAS (EBMT 2026) - "Consolidation with autologous transplant in patients with T-cell lymphoma offers survival rates above 70%. Carmustine based regimens like BEAM or, CBV, and bendamustine-based regimens were all equally effective. Achieving complete response prior to transplant and requiring fewer lines of therapy to achieve it are the most important variables for clinical decision-making."

Bone Marrow Transplantation • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK

SEQUENTIAL IMMUNOMODULATION WITH PRE-APHERESIS PRIMING AND POST-INFUSION BOOST TO RESTORE T-CELL FITNESS AND IMPROVE ANTI-CD19 CAR-T EXPANSION IN BENDAMUSTINE-EXPOSED R/R B-NHL: A PILOT STUDY (EBMT 2026) - P=N/A | "Pre-apheresis priming consisted of ibrutinib (420-560 mg/d) plus camrelizumab (200 mg IV q21d) for 1–2 cycles, followed by leukapheresis...Pomalidomide (2-4 mg PO daily, 14 days) was planned from day +3 as a post-infusion boost if clinically tolerated... This sequential strategy of pre-apheresis T-cell priming and post-infusion boosting appears feasible and demonstrates a manageable safety profile in heavily pre-treated, bendamustine-exposed R/R B-NHL patients. The intervention was associated with favorable changes in T-cell subsets and encouraging CAR-T expansion kinetics. These biological effects translated into a high initial response rate in a population with an otherwise poor prognosis."

CAR T-Cell Therapy • Clinical • Immunomodulating • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Richter's Syndrome • CCR7 • FAS

SALVAGE STRATEGIES AND OUTCOMES AFTER EARLY-LINE CD19 CAR T-CELL THERAPY FAILURE IN LARGE B-CELL LYMPHOMA (EBMT 2026) - "Prior CAR-T exposure included axicabtagene ciloleucel (51%), isoantigenic maraleucel (24%), tisagenlecleucel (22%), and point-of-care products (4%); 70% had received CAR-T therapy in the third-line setting.The overall response rate (ORR) to first salvage therapy was 50%, including 34% complete and 16% partial responses...1B–C), most commonly including bispecific antibodies (n=54), involved-site radiotherapy (n=40), bendamustine-based therapy (n=24), and polatuzumab-containing therapy (n=24); treatment categories were not mutually exclusive... In this large multicenter cohort of LBCL patients relapsing after early-line CD19 CAR-T therapy, salvage treatment achieved clinically meaningful responses regardless of prior CAR-T treatment line. Early post–CAR-T relapse identified a high-risk subgroup with poor outcomes. Immunotherapy-based salvage strategies showed the most favorable activity, supporting their preferential consideration and underscoring the need for prospective..."

CAR T-Cell Therapy • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

TREATMENT OUTCOMES WITH OUT-OF-SPECIFICATION PRODUCTS AND REMANUFACTURING SUCCESS IN CAR T-CELL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS: A MULTICENTRE REAL-WORLD STUDY GETH/GELTAMO (EBMT 2026) - "Final outcomes were OOS-infused (n=19), delayed-infused after remanufacturing (n=17) and non-infused (n=14).Among infused patients (n=36; axicabtagene ciloleucel 81%, tisagenlecleucel 19%), cytokine release syndrome occurred in 81% (grade ≥3: 3%) and ICANS in 55% (grade 3–4: 13%)...Age >60 years (p=0.04), double-hit lymphoma (p=0.028), shorter time from diagnosis to apheresis (p=0.014), primary refractory disease (p=0.008) and prior bendamustine exposure (9/50; p=0.049) were associated with inferior PFS... Manufacturing failure occurred in 4.13% of apheresis procedures, with nearly half of patients receiving CAR-T through OOS infusion or remanufacturing. Post-infusion outcomes were similar between OOS-infused and delayed-infused patients, while failure to reach infusion was associated with poor survival. These findings underscore the importance of optimized manufacturing pathways."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Immunology • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma

PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS ACHIEVE DEEP HEMATOLOGIC AND ORGAN RESPONSES WITH THE NOVEL MDC-CAR-BCMA001 (EBMT 2026) - " Seven patients were treated with a fixed dose of 800 x 106 BCMA-directed CAR T-cells after lymphodepleting chemotherapy with fludarabine/cyclophosphamide (4/7) or bendamustine (3/7 – in cases of neuropathy or severe nephropathy)...grade 3), rapidly resolving after tocilizumab and/or dexamethasone... MDC-CAR-BCMA001 shows a manageable toxicity profile with high efficacy even in heavily pretreated patients, making it a suitable construct for treating the vulnerable cohort of AL amyloidosis patients. Long-lasting, deep hematologic responses translate into excellent organ responses even in patients with advanced organ disease. These findings warrant further prospective evaluation, as planned in the phase I CLEAR AL trial (EU CT No."

Clinical • Amyloidosis • Hematological Malignancies • Inflammation • Monoclonal Gammopathy • Multiple Myeloma • Myositis • Renal Disease • Smoldering Multiple Myeloma

SAFETY AND EMERGING CLINICAL IMPACT OF CD19 CAR T-CELL THERAPY IN SEVERE AUTOIMMUNE RHEUMATIC DISEASES: A SINGLE-CENTRE CASE SERIES (EBMT 2026) - "All patients received lymphodepletion (mainly fludarabine/cyclophosphamide; dose-adjusted fludarabine for renal impairment; bendamustine as alternative in severe renal dysfunction) followed by a single KYV-101 infusion...All cases responded promptly to tocilizumab, and four patients received additional dexamethasone... In this cohort of patients with severe, treatment-refractory ARDs, KYV-101 induced rapid, profound B-cell depletion, leading to a durable, drug-free response with a manageable safety profile over ≥12 months. CRS events were uniformly low grade and controllable with early, protocolised intervention. Haematotoxicity, particularly neutropenia, including delayed episodes, represented a relevant component of the adverse event spectrum and responded to supportive care."

CAR T-Cell Therapy • Clinical • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Myositis • Nephrology • Neutropenia • Pneumonia • Rare Diseases • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

POST-TRANSPLANT COMPLICATIONS AND MAINTENANCE THERAPY IN CHILDREN UNDERGOING AUTOHSCT DUE TO RELAPSE/PROGRESSION OF HODGKIN'S LYMPHOMA (EBMT 2026) - "The first patient received 3 cycles of Brentuximab + Bendamustine and was qualified for alloHSCT; the second received Brentuximab + Bendamustine followed by Nivolumab—there was no response to the treatment, and the patient was referred to palliative care. Children treated for Hodgkin's lymphoma, due to a good response to the applied treatment, rarely require megachemotherapy and autoHSCT. In cases of relapse/progression, autoHSCT in most cases allows for achieving a lasting second remission. In patients with a poorer response to the applied treatment, maintenance therapy after autoHSCT should be considered."

Clinical • Post-transplantation • Bone Marrow Transplantation • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mucositis • Palliative care • Transplantation

CAR-T ACTIVITY FOR AUTOIMMUNE DISEASES ACROSS EBMT CENTERS IN 2025: A SURVEY ON BEHALF OF EBMT ADWP AND CTIWP (EBMT 2026) - "Lymphodepletion regimens largely mirrored those used in hematologic settings, with the majority of centers (93%) combining fludarabine and cyclophosphamide; only a small proportion of centers reported incorporating busulfan or bendamustine into their lymphodepleting regimens (5% and 2%, respectively). This multinational EBMT survey provides the first broad overview of the rapidly evolving adoption of CAR T-cell therapy for ADs. The field is expanding quickly, with increasing numbers of centers initiating programs, targeting both rheumatological and neurological diseases. Standardization of indications, right patient selection, multidisciplinary follow-up strategies, and reporting data in large multinational registries will be essential to guide this strategy toward wider clinical implementation."

CAR T-Cell Therapy • CNS Disorders • Glomerulonephritis • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Multiple Sclerosis • Myositis • Nephrology • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • CD20 • CD22

PICKING STRONG BRIDGING REGIMENS BEFORE CD19 CAR-T CELL THERAPY OF LARGE B CELL LYMPHOMA – HOW HISTOLOGY AND HIGH LDH IMPACT LONG-TERM OUTCOMES (EBMT 2026) - "Bridging choices were grouped as No-Bridging, radiotherapy, ancient (Pixantrone, CHOP-variants), intensive (e.g., R-DHAP, R-MATRIX), R-gemcitabine/oxaliplatin (R-GemOx), sequential, R-Polatuzumab (R-Pola), or R-Pola-Bendamustine (Pola-BR)... 508 patients (384 DLBCL-NOS, 124 trFL) treated with Axi-cel (65.2%), Tisa-cel (25.4%), or Liso-cel (9.4%) were included... Our dataset is limited by the retrospective nature including a possible bias that worse bridging outcome may prevent patients from CAR-T infusion. We found outcomes were distinct for trFL and DLBCL-NOS. In NOS, responses to bridging as well as any LDH-elevation strongly and independently influenced outcomes."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

IMPACT OF PRIOR B-CELL-DIRECTED IMMUNOTHERAPY ON THE OUTCOME OF CD19 CAR T-CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMA (EBMT 2026) - "Background: B-cell-directed immunotherapies (BCDI), such as CD19 chimeric antigen receptor T-cell therapy (CAR-T), antibody-drug conjugates including polatuzumab vedotin (pola), and bispecific antibodies (BSA) have revolutionized the treatment of large B-cell lymphoma (LBCL)...BCDI exposure (excluding rituximab) prior to CAR-T, including bridging therapy, was categorized as BSA, pola-based regimens, and other BCDI, including obinutuzumab, brentuximab vedotin, and loncastixumab tesirine...BCDI-exposed patients more often had ≥3 prior treatment lines (54.8% vs. 43.0%, p<0.001), more frequent axicabtagene ciloleucel usage (63.8% vs. 56.0%, p=0.012), and higher complete/partial remission (CR/PR) rates at lymphodepletion (40.2% vs. 29.1%, p<0.001).Three-year overall survival (OS) was numerically inferior with prior BCDI (41.3% vs. 49.7%, p=0.07), without differences in progression-free survival (PFS) (35.0% vs. 37.2%), relapse incidence (52.0% vs. 51.5%), or NRM (13.0%..."

CAR T-Cell Therapy • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

THREE-YEAR EFFICACY AND LONGITUDINAL SAFETY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH THIRD-LINE OR LATER (3L+) FOLLICULAR LYMPHOMA (FL) FROM TRANSCEND FL (EBMT 2026) - P2 | "In patients with 3L+ FL, a single infusion of liso-cel demonstrated remarkable efficacy, with durable responses and high 3-year survival rates, regardless of POD24 status or prior bendamustine exposure. No new safety signals were identified. Grade ≥ 3 neutropenia and hypogammaglobulinemia decreased over time and severe infections remained low, further underscoring the favorable long-term safety profile of liso-cel in patients with 3L+ FL.Table 1."

Clinical • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia

POST-TRANSPLANT COMPLICATIONS AND MAINTENANCE THERAPY IN CHILDREN UNDERGOING AUTOHSCT DUE TO RELAPSE/PROGRESSION OF HODGKIN'S LYMPHOMA (EBMT 2026) - "The first patient received 3 cycles of Brentuximab + Bendamustine and was qualified for alloHSCT; the second received Brentuximab + Bendamustine followed by Nivolumab—there was no response to the treatment, and the patient was referred to palliative care. Children treated for Hodgkin's lymphoma, due to a good response to the applied treatment, rarely require megachemotherapy and autoHSCT. In cases of relapse/progression, autoHSCT in most cases allows for achieving a lasting second remission. In patients with a poorer response to the applied treatment, maintenance therapy after autoHSCT should be considered."

Clinical • Post-transplantation • Bone Marrow Transplantation • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mucositis • Palliative care • Transplantation

SUCCESSFUL IMPLEMENTATION OF CAR-T CELL THERAPY AT THE ONCOLOGY INSTITUTE IN WARSAW (EBMT 2026) - "Cyclophosphamide and fludarabine were administered on days 5-3, followed by the CAR-T cell drug infusion Yescarta (DLBCL) or Tecartus (MCL), depending on the diagnosis...All MCL patients were treated with the R-CHOP/RDHAP regimen with autotransplantation consolidation, followed by ibrutinib (n=3) or acalabrutinib (n=2) in subsequent lines...Ten patients received bridging therapy before CAR-T therapy, Pola-BR or R-GEMOX chemotherapy for DLBCL, and R-bendamustine for MCL...Three patients required tocilizumab...Two patients received four doses of Anakinra... CAR-T therapy appears to be a safe and tolerable procedure despite the occurrence of profound neutropenia and the development of CRS and ICAN syndromes. Severe CRS and ICANS occurred in less than 15% of patients."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

SEQUENTIAL IMMUNOMODULATION WITH PRE-APHERESIS PRIMING AND POST-INFUSION BOOST TO RESTORE T-CELL FITNESS AND IMPROVE ANTI-CD19 CAR-T EXPANSION IN BENDAMUSTINE-EXPOSED R/R B-NHL: A PILOT STUDY (EBMT 2026) - P=N/A | "Pre-apheresis priming consisted of ibrutinib (420-560 mg/d) plus camrelizumab (200 mg IV q21d) for 1–2 cycles, followed by leukapheresis...Pomalidomide (2-4 mg PO daily, 14 days) was planned from day +3 as a post-infusion boost if clinically tolerated... This sequential strategy of pre-apheresis T-cell priming and post-infusion boosting appears feasible and demonstrates a manageable safety profile in heavily pre-treated, bendamustine-exposed R/R B-NHL patients. The intervention was associated with favorable changes in T-cell subsets and encouraging CAR-T expansion kinetics. These biological effects translated into a high initial response rate in a population with an otherwise poor prognosis."

CAR T-Cell Therapy • Clinical • Immunomodulating • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Richter's Syndrome • CCR7 • FAS

SAFETY AND EMERGING CLINICAL IMPACT OF CD19 CAR T-CELL THERAPY IN SEVERE AUTOIMMUNE RHEUMATIC DISEASES: A SINGLE-CENTRE CASE SERIES (EBMT 2026) - "All patients received lymphodepletion (mainly fludarabine/cyclophosphamide; dose-adjusted fludarabine for renal impairment; bendamustine as alternative in severe renal dysfunction) followed by a single KYV-101 infusion...All cases responded promptly to tocilizumab, and four patients received additional dexamethasone... In this cohort of patients with severe, treatment-refractory ARDs, KYV-101 induced rapid, profound B-cell depletion, leading to a durable, drug-free response with a manageable safety profile over ≥12 months. CRS events were uniformly low grade and controllable with early, protocolised intervention. Haematotoxicity, particularly neutropenia, including delayed episodes, represented a relevant component of the adverse event spectrum and responded to supportive care."

CAR T-Cell Therapy • Clinical • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Myositis • Nephrology • Neutropenia • Pneumonia • Rare Diseases • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

TREATMENT OUTCOMES WITH OUT-OF-SPECIFICATION PRODUCTS AND REMANUFACTURING SUCCESS IN CAR T-CELL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS: A MULTICENTRE REAL-WORLD STUDY GETH/GELTAMO (EBMT 2026) - "Final outcomes were OOS-infused (n=19), delayed-infused after remanufacturing (n=17) and non-infused (n=14).Among infused patients (n=36; axicabtagene ciloleucel 81%, tisagenlecleucel 19%), cytokine release syndrome occurred in 81% (grade ≥3: 3%) and ICANS in 55% (grade 3–4: 13%)...Age >60 years (p=0.04), double-hit lymphoma (p=0.028), shorter time from diagnosis to apheresis (p=0.014), primary refractory disease (p=0.008) and prior bendamustine exposure (9/50; p=0.049) were associated with inferior PFS... Manufacturing failure occurred in 4.13% of apheresis procedures, with nearly half of patients receiving CAR-T through OOS infusion or remanufacturing. Post-infusion outcomes were similar between OOS-infused and delayed-infused patients, while failure to reach infusion was associated with poor survival. These findings underscore the importance of optimized manufacturing pathways."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Immunology • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma

PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS ACHIEVE DEEP HEMATOLOGIC AND ORGAN RESPONSES WITH THE NOVEL MDC-CAR-BCMA001 (EBMT 2026) - " Seven patients were treated with a fixed dose of 800 x 106 BCMA-directed CAR T-cells after lymphodepleting chemotherapy with fludarabine/cyclophosphamide (4/7) or bendamustine (3/7 – in cases of neuropathy or severe nephropathy)...grade 3), rapidly resolving after tocilizumab and/or dexamethasone... MDC-CAR-BCMA001 shows a manageable toxicity profile with high efficacy even in heavily pretreated patients, making it a suitable construct for treating the vulnerable cohort of AL amyloidosis patients. Long-lasting, deep hematologic responses translate into excellent organ responses even in patients with advanced organ disease. These findings warrant further prospective evaluation, as planned in the phase I CLEAR AL trial (EU CT No."

Clinical • Amyloidosis • Hematological Malignancies • Inflammation • Monoclonal Gammopathy • Multiple Myeloma • Myositis • Renal Disease • Smoldering Multiple Myeloma